Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Half-year report · Q2

9776.TEDINET S100ULLX
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥10.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥19.7bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥9.9bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥338m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥291m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥343m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥515m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥296m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥344m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥386m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥222m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥380m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥226m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥226m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥226m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥16.4bnat 2024-09-30Cons.Assets
Total assets¥16.7bnat 2024-03-31Cons.Assets
Total assets¥16.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥5.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥5.5bnat 2024-03-31Cons.Liabilities
Net assets / equity¥11.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥11.2bnat 2024-03-31Cons.Net assets
Net assets / equity¥11.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥4.0bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥3.4bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.0bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥4.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥407m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥810m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥584m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥395m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥171m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥398m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥370m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥238m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥70.872024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥114.142023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.942023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio66.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio65.6%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio64.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥58m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥54m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30¥37m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥3.9bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥3.9bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥158m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥352m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥800m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥426m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥375m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2m
—segment totalrevenue2024-04-01 → 2024-09-30¥10.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥9.9bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥375m
—segment totalsegment profit2024-04-01 → 2024-09-30¥507m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥10.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥10.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥379m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥545m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥58m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥56m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥41m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥78m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥377m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥798m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥492m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥306m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7m
—segment totalrevenue2023-04-01 → 2023-09-30¥10.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥9.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥306m
—segment totalsegment profit2023-04-01 → 2023-09-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥10.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥308m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥489m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Allowance for doubtful accounts ioa by groupPrior1YearInstant-22369000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-22369000JPY
Investments and other assetsPrior1YearInstant696942000JPY
Investments and other assetsCurrentQuarterInstant656361000JPY
Noncurrent assetsPrior1YearInstant8984256000JPY
Noncurrent assetsCurrentQuarterInstant9330156000JPY
AssetsPrior1YearInstant16680947000JPY
AssetsCurrentQuarterInstant16408708000JPY
Notes and accounts payable tradePrior1YearInstant2235539000JPY
Notes and accounts payable tradeCurrentQuarterInstant2128266000JPY
Current portion of long term loans payablePrior1YearInstant135367000JPY
Current portion of long term loans payableCurrentQuarterInstant133692000JPY
Lease obligations clPrior1YearInstant125445000JPY
Lease obligations clCurrentQuarterInstant124353000JPY
Accounts payable otherPrior1YearInstant261365000JPY
Accounts payable otherCurrentQuarterInstant222210000JPY
Income taxes payablePrior1YearInstant156589000JPY
Income taxes payableCurrentQuarterInstant155402000JPY
Provision for bonusesPrior1YearInstant124463000JPY
Provision for bonusesCurrentQuarterInstant253523000JPY
Other clPrior1YearInstant268363000JPY
Other clCurrentQuarterInstant204015000JPY
Current liabilitiesPrior1YearInstant3307133000JPY
Current liabilitiesCurrentQuarterInstant3221464000JPY
Long term loans payablePrior1YearInstant1464937000JPY
Long term loans payableCurrentQuarterInstant1398091000JPY
Lease obligations nclPrior1YearInstant472843000JPY
Lease obligations nclCurrentQuarterInstant410751000JPY
Long term accounts payable otherPrior1YearInstant85502000JPY
Long term accounts payable otherCurrentQuarterInstant83081000JPY
Deferred tax liabilitiesPrior1YearInstant11563000JPY
Deferred tax liabilitiesCurrentQuarterInstant8381000JPY
Provision for directors retirement benefitsPrior1YearInstant70274000JPY
Provision for directors retirement benefitsCurrentQuarterInstant75229000JPY
Net defined benefit liabilityPrior1YearInstant21699000JPY
Net defined benefit liabilityCurrentQuarterInstant21546000JPY
Other nclPrior1YearInstant63953000JPY
Other nclCurrentQuarterInstant63953000JPY
Noncurrent liabilitiesPrior1YearInstant2190773000JPY
Noncurrent liabilitiesCurrentQuarterInstant2061034000JPY
LiabilitiesPrior1YearInstant5497907000JPY
LiabilitiesCurrentQuarterInstant5282498000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentQuarterInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentQuarterInstant1015270000JPY
Retained earningsPrior1YearInstant9607738000JPY
Retained earningsCurrentQuarterInstant9753543000JPY
Treasury stockPrior1YearInstant-757451000JPY
Treasury stockCurrentQuarterInstant-947426000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass